134149-40-9

Upstream product

• 532-20-7 D-Ribose 
• 107-18-6 allyl alcohol 
• 58-86-6 D-xylose 
• 50-69-1 D-ribose 
• 106-95-6 allyl bromide 
• 5328-37-0 L-arabinose 
• 532-20-7 L-arabinose 

Downstream Products

• 934822-33-0 allyl 3-nitro-3-deoxy-6-O-tosyl-β-D-glucopyranoside 
• 134149-36-3 prop-1-enyl 2,3,5-tri-O-benzyl-α,β-L-arabinofuranoside 
• 89615-42-9 2,3,5-tri-O-benzyl-β-L-arabinofuranose 
• 121682-55-1 allyl-2,3,5-tri-O-benzyl-α,β-L-arabinofuranoside 

Relevant academic research and scientific papers

Synthesis of the spirastrellolide A, B/C spiroketal: Enabling solutions for problematic au(I)-catalyzed spiroketalizations

A synthesis of the spirastrellolide A, B/C-ring monounsaturated spiroketal is reported. The key step relies on a Au-catalyzed spiroketalization of a propargyl triol employing an acetonide as a regioselectivity regulator. Through observation and analysis, a set of conditions has been developed that facilitates the use of a mixture of diastereomeric substrates, obviating the need to control the stereochemistry of the propargyl stereocenter and enabling a convenient retrosynthetic disconnection. The key reaction proceeds in 80% yield in 1 min at ambient temperature with the Me3PAuCl/AgOTf catalyst system. These conditions should be widely applicable for new synthetic endeavors as they appear to overcome all issues with the Au-catalyzed spiroketalization.

Anomeric alkylations and acylations of unprotected mono- and disaccharides mediated by pyridoneimine in aqueous solutions

A site-specific deprotonation followed by alkylations and acylations of sugar hemiacetals to the corresponding alkyl glycosides and acylated sugars in aqueous solutions is disclosed herein. Pyridoneimine as a new base is developed to mediate the deprotonation of readily available sugar hemiacetals and further reactions with alkylation and acylation agents.

Sulfonated graphene oxide as highly efficient catalyst for glycosylation

Heterogeneous sulfonated graphene oxide for the first time has been used as a green and efficient catalyst for atom-economic glycosylation of unprotected, unactivated glycosyl donors or 2,3,4,6-tetra-O-acetylglycosyltrichloroacetimidate with various accep

Direct glycosylation of unprotected and unactivated carbohydrates under mild conditions

Ligand exchange acetalization of acetals in the presence of catalytic amounts of mandelic acid and titanium tert-butoxide is reported. This transformation is successfully extended to glycosylation of unprotected and unactivated pentoses. Even unreactive pentoses such as d-arabinose or d-lyxose can be transformed by this new methodology into corresponding isopropyl glycosides.

Green glycosylation promoted by reusable biomass carbonaceous solid acid: An easy access to β-stereoselective terpene galactosides

An efficient green protocol has been developed for the atom economic glycosylation of unprotected, unactivated glycosyl donors and glycosylation of glycosyl trichloroacetimidates with the aid of reusable eco-friendly biomass carbonaceous solid acid as catalyst. The Royal Society of Chemistry.

Synthesis of congeners of migrastatin and dorrigocin A from d-xylose

Migrastatin and dorrigocin A analogues have potential as anti-metastatic agents that act by targeting the actin-bundling protein, fascin. Syntheses of close structural analogues of these agents have been achieved. Wittig and Ando olefination reactions with an aldehyde obtained from d-xylose, respectively, gave two trisubstituted alkene intermediates that were then elaborated into either macrolactone or macrolactam analogues of migrastatin or to an acyclic dorrigocin A analogue.

Carbohydrate mimic of 2-deoxystreptamine for the preparation of conformationally constrained aminoglycosides

The synthesis of a carbohydrate mimic of 2-deoxystreptamine (2-DOS) is described starting from d-ribose. Crucial steps of the synthesis involve a stereoselective nitroaldol condensation and deoxygenation via elimination-in situ reduction. Moreover, glycos

ANALOGUES OF COFORMYCIN AND THEIR USE FOR TREATING PROTOZOAN PARASITE INFECTIONS

This invention relates to compounds that are analogues of coformycin, pharmaceutical compositions containing the compounds, and methods of using the compounds for treating protozoan parasite infections, especially malaria.